Latest Breaking News On - Alvogen pharmaceuticals - Page 1 : vimarsana.com

NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression -January 22, 2024 at 06:49 am EST

Exceeded originally target enrollment with n=74                       Last patient, last visit expected in approximately six weeks; data to follow shortly thereafterPositive...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination -January 17, 2024 at 06:49 am EST

RADNOR, Pa., Jan. 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing therapies for suicidal depression, chronic pain, and PTSD, today...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard -January 02, 2024 at 06:49 am EST

Company to present full compliance plan, based on achieving clinical milestones, to Nasdaq on January 4, 2024RADNOR, Pa., Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage...

NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard

NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco

NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco -January 02, 2024 at 08:46 am EST

The benefits of ketamine are clear, but so are the risksKetamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more...

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors

Former Inspector General, US Dept. of Health and Human ServicesFormer Assistant US Attorney for the Eastern District of VirginiaNationally recognized attorney in highly regulated industries;...

NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatm